Hematopoietic Stem Cell Transplantation for Systemic Lupus ErythematosusReport as inadecuate

Hematopoietic Stem Cell Transplantation for Systemic Lupus Erythematosus - Download this document for free, or read online. Document in PDF available to download.

Clinical and Developmental ImmunologyVolume 2012 2012, Article ID 380391, 9 pages

Review ArticleDivision of Hematology and Stem Cell Transplantation, IRCCS Azienda Ospedaliera Universitaria San Martino-IST, Genoa, Italy

Received 9 March 2012; Revised 6 June 2012; Accepted 3 July 2012

Academic Editor: Roberto Caricchio

Copyright © 2012 Alberto M. Marmont du Haut Champ. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Two streams of research are at the origin of the utilization of hematopoietic stem cell transplantation HSCT for severe autoimmune diseases SADs. The allogeneic approach came from experimental studies on lupus mice, besides clinical results in coincidental diseases. The autologous procedure was encouraged by researches on experimental neurological and rheumatic disorders. At present the number of allogeneic HSCT performed for human SADs can be estimated to not over 100 patients, and the results are not greatly encouraging, considering the significant transplant-related mortality TRM and the occasional development of a new autoimmune disorder and-or relapses notwithstanding full donor chimerism. Autologous HSCT for refractory SLE has become a major target. Severe cases have been salvaged, TRM is low and diminishing, and prolonged clinical remissions are obtainable. Two types of immune resetting have been established, “re-education” and regulatory T cell Tregs normalization. Allogeneic HSCT for SLE seems best indicated for patients with disease complicated by an oncohematologic malignancy. Autologous HSCT is a powerful salvage therapy for otherwise intractable SLE. The duration of remission in uncertain, but a favorable response to previously inactive treatments is a generally constant feature. The comparison with new biological agents, or the combination of both, are to be ascertained.

Author: Alberto M. Marmont du Haut Champ

Source: https://www.hindawi.com/


Related documents